Cubist Systematic Strategies, LLC Myovant Sciences Ltd. Transaction History

Cubist Systematic Strategies, LLC

$15.8 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$24.03 - $27.02 $1.54 Million - $1.74 Million	-64,281 Reduced 75.32%	21,064 $567,000
Q3 2022 Nov 14, 2022	BUY	$11.6 - $20.44 $518,624 - $913,851	44,709 Added 110.02%	85,345 $1.53 Million
Q2 2022 Aug 15, 2022	BUY	$7.78 - $14.69 $44,159 - $83,380	5,676 Added 16.24%	40,636 $505,000
Q1 2022 May 16, 2022	BUY	$11.38 - $16.4 $157,442 - $226,893	13,835 Added 65.49%	34,960 $466,000
Q4 2021 Feb 14, 2022	SELL	$14.31 - $23.87 $349,564 - $583,096	-24,428 Reduced 53.63%	21,125 $329,000
Q3 2021 Nov 15, 2021	BUY	$18.94 - $26.99 $628,883 - $896,175	33,204 Added 268.88%	45,553 $1.02 Million
Q2 2021 Aug 16, 2021	SELL	$17.07 - $24.56 $21,764 - $31,314	-1,275 Reduced 9.36%	12,349 $281,000
Q1 2021 May 17, 2021	SELL	$20.46 - $25.18 $407,092 - $501,006	-19,897 Reduced 59.36%	13,624 $280,000
Q4 2020 Feb 16, 2021	BUY	$13.8 - $27.62 $306,153 - $612,749	22,185 Added 195.7%	33,521 $926,000
Q3 2020 Nov 16, 2020	SELL	$14.05 - $22.6 $130,960 - $210,654	-9,321 Reduced 45.12%	11,336 $159,000
Q2 2020 Aug 14, 2020	SELL	$7.34 - $20.84 $279,698 - $794,129	-38,106 Reduced 64.85%	20,657 $426,000
Q1 2020 May 15, 2020	BUY	$6.55 - $14.76 $64,995 - $146,463	9,923 Added 20.32%	58,763 $444,000
Q4 2019 Feb 14, 2020	BUY	$4.2 - $19.21 $36,514 - $167,011	8,694 Added 21.66%	48,840 $758,000
Q3 2019 Nov 14, 2019	BUY	$5.19 - $9.46 $19,031 - $34,689	3,667 Added 10.05%	40,146 $209,000
Q2 2019 Aug 14, 2019	BUY	$8.69 - $25.0 $317,002 - $911,975	36,479 New	36,479 $330,000
Q4 2017 Feb 14, 2018	SELL	$11.37 - $16.4 $2,080 - $3,001	-183 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$9.93 - $15.47 $1,817 - $2,831	183	183 $3,000

Others Institutions Holding MYOV

# of Institutions

Shares Held

61.3K

Call Options Held

Put Options Held

View Full List

About Myovant Sciences Ltd.

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

More about MYOV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Account